CD4 and neoplasm: In vitro studies showed that agonistic engagement of SLAMF7 on tumor-specific CD4+ T-cells enhanced their cytolytic activity, which, if expressed by CD4+ T-cells in these tumors, may explain the relationship with favorable prognosis (22).